Pan‐Chyr Yang
National Taiwan University · 1,231 works · 58,308 citations · h-index 117
Top works
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
- MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
- Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications
- Pulmonary Sequelae in Convalescent Patients after Severe Acute Respiratory Syndrome: Evaluation with Thin-Section CT
- A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)
- Early detection of hepatocellular carcinoma by real-time ultrasonography. A prospective study
- A Five-Gene Signature and Clinical Outcome in Non–Small-Cell Lung Cancer
- Detection of SARS-associated Coronavirus in Throat Wash and Saliva in Early Diagnosis
- Profiling Expression Patterns and Isolating Differentially Expressed Genes by cDNA Microarray System with Colorimetry Detection
- Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus
- MicroRNA Signature Predicts Survival and Relapse in Lung Cancer
- Value of sonography in determining the nature of pleural effusion: analysis of 320 cases.
- Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy
- Pretreatment Epidermal Growth Factor Receptor ( EGFR ) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer
- Clinical Manifestations, Laboratory Findings, and Treatment Outcomes of SARS Patients
- Microbiologic Characteristics, Serologic Responses, and Clinical Manifestations in Severe Acute Respiratory Syndrome, Taiwan1
- Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: International Multidisciplinary Classification of Lung Adenocarcinoma: Executive Summary
- Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer
- Ultrasonographic Evaluation of Pulmonary Consolidation